The preferred solid dosage form for mebeverine is typically a sustained-release capsule.Rationale for Sustained-Release Capsules

	o	Controlled Release:
Mebeverine is an antispasmodic used primarily for the treatment of irritable bowel syndrome (IBS) and other gastrointestinal disorders.A sustained-release capsule ensures a gradual release of the drug, maintaining consistent plasma levels over a prolonged period.o	Reduction in Dosage Frequency:
Sustained-release capsules reduce the frequency of administration (usually to twice daily instead of thrice daily for immediate-release tablets).o	Minimized Side Effects:
A controlled release reduces the risk of peak plasma concentrations that can cause dose-related side effects, such as nausea or dizziness.Physicochemical and Pharmacokinetic Properties of Mebeverine

	o	Short Half-Life:
Mebeverine has a relatively short half-life (~2 hours), which makes it ideal for sustained-release formulations to prolong its action.o	Enhanced Patient Comfort:
By avoiding frequent dosing, sustained-release formulations improve the quality of life for patients with chronic conditions like IBS.o	Sensitive to First-Pass Metabolism:
Mebeverine undergoes extensive first-pass metabolism, forming active metabolites.Sustained-release formulations help reduce fluctuations in drug levels and ensure a steady therapeutic effect.This choice is made to enhance its therapeutic efficacy and improve patient compliance.This increases convenience and adherence to the prescribed regimen.2.